Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Entellus’ ENT portfolio is led by e XprESS Multi-Sinus Dilation System and the LATERA Absorbable Nasal Implant.
Pfizer is no stranger to taking the big gambles-note the company’s attempts to buy Astra in 2014 and Allergan in 2016.
The revised offer of $49.25 per share represents an increase of 17.3 percent to the previously announced $42 per share, the company said.
Siemens Healthineers, the German industrial conglomerate’s largest and most profitable division, is worth roughly $47.49 billion.
Astellas is pulling the trigger on an acquisition option from a partnership deal the two companies formed in 2013.
Genmab just received a $20M milestone payment from Janssen Biotech.
The company has snapped up manufacturing space in North Carolina’s Research Triangle Park to internally produce lentiviral vector for the company’s gene and cell therapies.
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics.
A look at why a potential buyout of Acadia might not be as likely as some have suggested.
Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative.